-
JP Morgan Raises PT On Celgene To $70
Monday, June 6, 2011 - 6:02am | 26JP Morgan has raised the price target on Celgene (NASDAQ: CELG) from $65 to $70 and maintains its Overweight rating.
-
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
Friday, June 3, 2011 - 3:01pm | 114EntreMed, Inc. (Nasdaq: ENMD) today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. ENMD-2076 demonstrated clinical activity when administered daily orally as a single agent. Interim data from 57 evaluable patients...
-
Options Brief: GTx, Inc.
Friday, June 3, 2011 - 1:10pm | 85Shares of GTx, Inc. (NASDAQ: GTXI) are lower on the session by 0.50%, trading at $6.03. Overall call volume is now running at 5.15x the daily average, with 89% of all calls traded being purchases on the offer. 1,376 contracts have traded on the session so far. GTx, Inc. is a biopharmaceutical...
-
Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks
Friday, June 3, 2011 - 11:35am | 1743Point Roberts, WA - June 3, 2011 - Investorideas.com, a leader in sector stock issues a trading alert for biotech/pharma stocks Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc (VRTX). Merck & Company, Inc.(NYSE: MRK) following recent news and developments for the treatment of...
-
Puts Purchased on Keryx Biopharmaceuticals, Inc.
Friday, June 3, 2011 - 11:14am | 121Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) are lower on the session by 1.63%, currently trading at $5.13. The stock has been moving largely higher over the past four months and is currently trading above the 200-day moving average. Options traders are buying puts on the name today. A...
-
Goldman Sachs Suggests Buying Calls on United Therapeutics
Friday, June 3, 2011 - 9:10am | 170Goldman Sachs is out with a research report this morning, where it suggests that traders buy calls on United Therapeutics Corporation (NASDAQ: UTHR) ahead of upcoming data. Goldman Sachs SMid Cap Biotech Analyst, Terence Flynn, is positive on the potential for key Phase 3 data expected this month...
-
Ligand and Medicines Company Agree to Worldwide License for Proprietary Captisol®-Enabled Intravenous Formulation of Clopidogrel
Friday, June 3, 2011 - 9:06am | 160Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Medicines Company (NASDAQ: MDCO) announced today a licensing agreement under which Ligand has licensed exclusive worldwide rights to The Medicines Company for Ligand's Captisol®-enabled intravenous formulation of clopidogrel. Clopidogrel is...
-
Benzinga's Top Pre-Market NASDAQ Losers
Friday, June 3, 2011 - 8:17am | 115Orexigen Therapeutics Inc (NASDAQ: OREX) dipped 26.73% to $2.33 in the pre-market session. Orexigen put the further development of its obesity drug candidate Contrave on hold. ARM Holdings plc (NASDAQ: ARMH) dropped 1.47% to $28.06 in the pre-market trading. ARMH's PEG ratio is 3.04. Randgold...
-
Benzinga's Top Downgrades
Friday, June 3, 2011 - 8:16am | 136Analysts at Robert W. Baird downgraded Theravance Inc (NASDAQ: THRX) from “outperform” to “neutral.” THRX's shares closed at $23.51 yesterday. Theravance's trailing-twelve-month operating margin is -316.07%. Analysts at HSBC Securities downgraded Shanda Interactive Entertainment Ltd (NASDAQ: SNDA...
-
Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting
Friday, June 3, 2011 - 8:03am | 233Peregrine Pharmaceuticals (NASDAQ: PPHM) today is presenting data from a Phase II trial of Cotara in recurrent glioblastoma multiforme at an oral poster discussion at 5:00 PM CDT at the Annual Meeting of the American Society of Clinical Oncology. In 41 patients treated at first relapse with a...
-
Orexigen Therapeutics Getting Crushed As Company Puts Obesity Drug On Hold
Friday, June 3, 2011 - 7:59am | 121Orexigen Therapeutics, Inc. (NASDAQ: OREX) shares are getting killed this morning, losing a third of their value as the company is putting its obesity drug, Contrave on hold. The company said that regulators are making "unprecedented" demands about safety trials for the drug. Oreixigen says the...
-
Goldman Sachs Reiterates Neutral on United Therapeutics Corporation
Friday, June 3, 2011 - 7:58am | 163Goldman Sachs reiterated its Neutral rating on United Therapeutics Corporation (NASDAQ: UTHR). United Therapeutics is expected to announce the Phase 3 data for its new drug Remodulin. Goldman feels the results will be better than other analysts predict. In a research report published today,...
-
Bank of America Merrill Lynch Reports on Alexion Pharmaceuticals
Friday, June 3, 2011 - 7:56am | 233Bank of America Merrill Lynch commented on Alexion Pharmaceuticals (NYSE: ALXN) in a report released today. In the report, Bank of America Merrill Lynch was positive in its assessment of the company. Bank of America Merrill Lynch writes, "We reiterate our Buy rating as we believe additional...
-
Bank of America Merrill Lynch Reports on Biogen Idec
Friday, June 3, 2011 - 7:53am | 190Bank of America Merrill Lynch commented on Biogen Idec (NASDAQ: BIIB) in a report released today. In the report, Bank of America Merrill Lynch was positive in its assessment of the company. Bank of America Merrill Lynch writes, "We reiterate our BUY rating and see three reasons for upside in the...
-
Citi Reports Pharmasset Price Target Of $200
Friday, June 3, 2011 - 7:43am | 99According to Citi, Pharmasset (NASDAQ: VRUS) 12-month target price of $200 is based on DCF analysis using a 10% discount rate that runs through 2025 with no terminal growth rate. Citi said that it believes that a 10% discount rate reflects a normalized rate that is appropriate given historical...